Peptide Half-Life, Bioavailability, and Timing: The Complete Research Guide for 75 Compounds
By RUOcodes.com Research Team
Published: · Updated: Sep 6, 2026
Complete guide to peptide half-life and bioavailability: how route of administration, storage, and timing affect active compound levels.
For research and educational purposes only. Not medical advice. Values reflect best available published data from animal studies, limited human pharmacokinetic trials, and validated clinical prescribing information where applicable. Where human data is absent, values are estimated from preclinical models and detection window analysis. TL;DR Half-life determines how long a compound stays active, and every dosing decision flows from it. Getting it wrong means either inadequate exposure or dangerous accumulation. This guide covers half-life, bioavailability, duration of active effect, steady-state timing, washout periods, and dosing frequency for 75 peptides, bioregulators, and research compounds across 13 functional categories. Key takeaways: it takes 4–5 half-lives to reach steady-state and 4–5 half-lives to wash out; Khavinson bioregulators have 15-minute plasma half-lives but months-long biological effects; Noopept is a prodrug and the parent plasma half-life is irrelevant for timing; GLP-1 compounds require 4–5 weeks of weekly dosing before you are measuring steady-state effects. Use the searchable reference table below to find any compound instantly. Why This Guide Exists If you have spent any time in the research peptide space, you have encountered this scenario. Someone is three weeks into a protocol, frustrated that they are not observing the effects they expected, and they start questioning the vendor or the compound. The peptide COA is clean. The vendor is vetted. The sourcing is legitimate. The problem is not the compound. The problem is the pharmacokinetics. They are running a compound with a 7-day half-life and measuring outcomes at week two — during the accumulation phase before steady-state has been reached. Or they are timing doses based on the plasma half-life of a prodrug rather than the active metabolite. Or they are stacking two compounds with dramatically different half-lives and attributing effects to the wrong variable. These are not exotic rese…
← Back to Blog